OBJECTIVES: Acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains associated with significant mortality despite the widespread application of early revascularization strategies. Recent evidence suggests that the use of intra-aortic balloon pump (IABP) counterpulsation does not improve mortality in this cohort of patients. We summarize our experience with mechanical circulatory support (MCS) therapy for AMI/CS. METHODS: This is a retrospective review of 61 patients who received MCS therapy for AMI/CS at our institution between March 2007 and March 2013. RESULTS: Mean age was 60.2 ± 10.3 years; mean ejection fraction was 24 ± 15% and 29% of patients were receiving active cardiopulmonary resuscitation at the time of support initiation. Prior to the initiation of MCS, 70.5% of patients had an IABP. Mean arterial pressure improved significantly with MCS (63 mmHg prior to MCS, 82 mmHg after MCS, P ≤ 0.01). Mean length of support was 9.5 ± 11.0 days, and overall survival to 30 days was 59.0%. Among 30-day survivors, 44.4% required device exchange to a durable MCS device. Ultimately, only 31% (52.8% of patients who survived to 30 days) achieved myocardial recovery. CONCLUSIONS: Short-term MCS therapy with subsequent aggressive use of durable MCS device may improve the unacceptably high mortality rate in AMI/CS. Rigorous prospective studies of MCS therapy in AMI/CS are warranted.
OBJECTIVES: Acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains associated with significant mortality despite the widespread application of early revascularization strategies. Recent evidence suggests that the use of intra-aortic balloon pump (IABP) counterpulsation does not improve mortality in this cohort of patients. We summarize our experience with mechanical circulatory support (MCS) therapy for AMI/CS. METHODS: This is a retrospective review of 61 patients who received MCS therapy for AMI/CS at our institution between March 2007 and March 2013. RESULTS: Mean age was 60.2 ± 10.3 years; mean ejection fraction was 24 ± 15% and 29% of patients were receiving active cardiopulmonary resuscitation at the time of support initiation. Prior to the initiation of MCS, 70.5% of patients had an IABP. Mean arterial pressure improved significantly with MCS (63 mmHg prior to MCS, 82 mmHg after MCS, P ≤ 0.01). Mean length of support was 9.5 ± 11.0 days, and overall survival to 30 days was 59.0%. Among 30-day survivors, 44.4% required device exchange to a durable MCS device. Ultimately, only 31% (52.8% of patients who survived to 30 days) achieved myocardial recovery. CONCLUSIONS: Short-term MCS therapy with subsequent aggressive use of durable MCS device may improve the unacceptably high mortality rate in AMI/CS. Rigorous prospective studies of MCS therapy in AMI/CS are warranted.
Authors: Deepak Acharya; Renzo Y Loyaga-Rendon; Salpy V Pamboukian; José A Tallaj; William L Holman; Ryan S Cantor; David C Naftel; James K Kirklin Journal: J Am Coll Cardiol Date: 2016-04-26 Impact factor: 24.094
Authors: Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph Journal: Cardiovasc Diagn Ther Date: 2020-10
Authors: A Reshad Garan; Waqas A Malick; Marlena Habal; Veli K Topkara; Justin Fried; Amirali Masoumi; Aws K Hasan; Dimitri Karmpaliotis; Ajay Kirtane; Melana Yuzefpolskaya; Maryjane Farr; Yoshifumi Naka; Dan Burkhoff; Paolo C Colombo; Paul Kurlansky; Hiroo Takayama; Koji Takeda Journal: ASAIO J Date: 2019 Nov/Dec Impact factor: 2.872
Authors: Deepak Acharya; Brian C Gulack; Renzo Y Loyaga-Rendon; James E Davies; Xia He; J Matthew Brennan; Vinod H Thourani; Matthew L Williams Journal: Ann Thorac Surg Date: 2015-12-22 Impact factor: 4.330
Authors: Sanjeet Singh Avtaar Singh; Sudeep Das De; Francesco Nappi; Ahmed Al-Adhami; Yasser Hegazy; Jonathan Dalzell; Harikrishna Doshi; Andrew Sinclair; Philip Curry; Mark Petrie; Colin Berry; Nawwar Al-Attar Journal: J Thorac Dis Date: 2019-02 Impact factor: 2.895
Authors: Georg Trummer; Alexander Supady; Friedhelm Beyersdorf; Christian Scherer; Tobias Wengenmayer; Markus Umhau; Christoph Benk Journal: Scand J Trauma Resusc Emerg Med Date: 2017-07-10 Impact factor: 2.953